Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

HighTower Advisors LLC raised its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 2.4% during the fourth quarter, ...

Globus Medical (NYSE:GMED – Get Free Report)‘s stock had its “hold” rating restated by equities researchers at Needham & ...

Learn more about whether Globus Medical, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor ...

According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers. Did you ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of ...

Alternatively, shareholders may receive a hard copy of the 2024 Annual Report on Form 20-F, free of charge, by request to Globus’ Investor Relations Advisor at: Capital Link Inc. 230 Park Avenue, ...

Medtech company Globus Medical has expanded its spine portfolio by launching its Cohere anterior lumbar interbody fusion spacer and Modulus ALIF blades. The Cohere space is the first porous ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...